Navigation Links
FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
Date:2/4/2011

res, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Item 1—"Business—(b) Significant Recent Developments—Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Form 10-K for fiscal 2010;
  • the two agreements between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") pertaining to the exclusion of our former chief executive officer from participation in federal healthcare programs and pertaining to the dissolution of our ETHEX subsidiary, in order to resolve the risk of potential exclusion of our company, as more fully described in Note 15—"Commitments and Contingencies—Litigation and Governmental Inquiries" of the Notes to the Consolidated Financial Statements included in the Form 10-K for fiscal 2010;
  • the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Item 1—"Business—(b) Significant Recent Developments—Plea Agreement with the U.S. Department of Justice" in the Form 10-K for fiscal 2010;
  • changes in the current and future business environment, including interest rates and capital and consumer spending;
  • the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;
  • the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations, including the risk of obtaining necessary state licenses in a timely manner;
  • fluctuations in revenues;
  • the difficulty of predicting the pattern of inventory movements by the Company's customers;
  • the impact
    '/>"/>

  • SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. FDA Approves Viibryd to Treat Major Depressive Disorder
    2. FDA Approves Head Lice Treatment for Children and Adults
    3. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
    4. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
    5. FDA Approves New Dosage Strength for INTELENCE®
    6. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
    7. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
    8. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
    9. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
    10. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
    11. FDA Approves New Treatment Option for Late-Stage Breast Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
    (Date:7/30/2015)... , July 30, 2015 Vermillion, ... on gynecologic disease, announced today it will ... after the market close on Thursday, August ... call and webcast at 4:30pm Eastern.Conference Call ... at 4:30pm Eastern/1:30pm Pacific  Domestic: ...
    (Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
    Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
    (Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
    (Date:7/30/2015)... Dana Point, CA (PRWEB) , ... July 30, 2015 , ... ... the highest honors available, including the very rare “no recommendations.” No recommendations means CARF ... full compliance; this is a notation that less than 3% of all facilities receive. ...
    (Date:7/30/2015)... Alexandria, VA (PRWEB) , ... July 30, 2015 ... ... applauds Drug Enforcement Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution ... been scheduled for Saturday, September 26, 2015 from 10:00 AM to 2:00 PM ...
    (Date:7/30/2015)... ... July 30, 2015 , ... The Tisch ... Institute Designation , The Tisch Cancer Institute (TCI) at the Icahn School of ... center. TCI joins an elite group of 69 cancer institutions nationwide that have ...
    (Date:7/30/2015)... PA (PRWEB) , ... July 30, 2015 , ... ... inventor from Texas, has designed a personal-care device that makes it easy to apply ... Buddy” could eliminate the need for assistance when applying lotion or medication to the ...
    Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
    ... for the Fourth Quarter was $ 0.28 per share ... the Year ... End, LANCASTER, Pa., Oct. 11 Herley Industries,Inc. (Nasdaq: HRLY ) today reported ... income during the fourth quarter of 2007 was $3.8 million or $.28,per share, as compared ...
    ... a simple tool that can improve the effectiveness of ... result in dramatic improvements in health and safety. , ... with color images of the medication to be taken ... in a patient,s native language if the patient does ...
    ... Oct. 11 The law firm of Kohn, Swift ... has been,commenced against Pall Corporation ("Pall" or the "Company") ... States District Court for the Eastern,District of New York, ... of all investors who purchased Pall securities between April,20, ...
    ... Tahoe, CA, October 11, 2007 Cancer researchers have ... after the use of therapies designed to stop the ... cell growth. New research has now detected that androgen-synthesizing ... cancer cells may develop the capacity to produce their ...
    ... implicated in prostate and breast cancer development may also ... Researchers at the Kimmel Cancer Center at Jefferson in ... normally applies the brakes on a cancer-causing gene ... Though the work is preliminary, the scientists say, the ...
    ... CHESHIRE, Conn., Oct. 11 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... conference call and audio web cast on Thursday, October ... with the release of its,financial results for the third ... results at 6:30 a.m. ET on Thursday,October 25, 2007. ...
    Cached Medicine News:Health News:Herley Reports 4th Quarter and Year-End Results 2Health News:Herley Reports 4th Quarter and Year-End Results 3Health News:Herley Reports 4th Quarter and Year-End Results 4Health News:Herley Reports 4th Quarter and Year-End Results 5Health News:Herley Reports 4th Quarter and Year-End Results 6Health News:Herley Reports 4th Quarter and Year-End Results 7Health News:Herley Reports 4th Quarter and Year-End Results 8Health News:Herley Reports 4th Quarter and Year-End Results 9Health News:Herley Reports 4th Quarter and Year-End Results 10Health News:Herley Reports 4th Quarter and Year-End Results 11Health News:Improving doctor-patient communication yields significant health benefits 2Health News:Improving doctor-patient communication yields significant health benefits 3Health News:Improving doctor-patient communication yields significant health benefits 4Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 2Health News:Kohn, Swift & Graf, P.C. Announces Commencement of Lawsuit Against Pall Corporation-PLL 3Health News:New research may show why some prostate cancer recurs after treatment 2Health News:New research may show why some prostate cancer recurs after treatment 3Health News:Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer 2
    Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
    Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
    The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
    The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
    Medicine Products: